SCHEMBL25375220

SCHEMBL25375220

Nc1ncc(-c2ccncc2F)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.56
NUDT1 P36639 2/20 0.43
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
CSNK2A1 P68400 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
BACE1 P56817 1/20 0.37
PRKCB P05771 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCE Q02156 1/20 0.36
PRKCQ Q04759 1/20 0.36
PRKCD Q05655 1/20 0.36
PIP4K2C Q8TBX8 1/20 0.36
LATS1 O95835 2/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482474 1.00 LIMK1 (0.56) LIMK1NUDT1NPC1ALDH1A1MAPT
SCHEMBL16513325 0.79 LIMK1 (0.56) LIMK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL29993395 0.79 ALDH1A1 (0.53) LIMK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL2404342 0.79 ALDH1A1 (0.53) LIMK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL26192388 0.77 CYP2A6 (0.51) LIMK1NUDT1LOXL2PRKCBPRKCH
SCHEMBL15641400 0.76 CLK1 (0.43) LIMK1NPC1ALDH1A1MAPTRAB9A
SCHEMBL17836550 0.72 KDM4E (0.64) NUDT1NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL16513215 0.72 LIMK1 (1.00) LIMK1ALDH1A1KDM4EMAPK14
SCHEMBL31301232 0.72 NUDT1 (0.57) NUDT1LOXL2LATS1LATS2
SCHEMBL5960025 0.72 CSNK2A1 (0.56) LIMK1NPC1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170107-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. 2025-05-29 US disclosed
EP-4469035-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE Bridgene Biosciences, Inc. (US) 2024-12-04 EP disclosed
WO-2023146786-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. (US) 2023-08-03 WO disclosed
WO-2023146786-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170107-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE ABL1, LCK, SRC LIMK1 438/4885NUDT1 800/4885NPC1 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.